<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2017-09-06" updated="2019-12-02">
  <drugbank-id primary="true">DB13882</drugbank-id>
  <name>Methyl nicotinate</name>
  <description>Methyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain. The action of methyl nicotinate as a rubefacient is thought to involve peripheral vasodilation. For veterinary purposes, methyl nicotinate is used to treat respiratory diseases, vascular disorders, rheumatoid arthritis, and muscle and joint pains [F64].</description>
  <cas-number>93-60-7</cas-number>
  <unii>7B1AVU9DJN</unii>
  <average-mass>137.136</average-mass>
  <monoisotopic-mass>137.047678473</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A33027</ref-id>
        <pubmed-id>14550884</pubmed-id>
        <citation>Muller B, Kasper M, Surber C, Imanidis G: Permeation, metabolism and site of action concentration of nicotinic acid derivatives in human skin. Correlation with topical pharmacological effect. Eur J Pharm Sci. 2003 Oct;20(2):181-95.</citation>
      </article>
      <article>
        <ref-id>A33028</ref-id>
        <pubmed-id>2317445</pubmed-id>
        <citation>Roskos KV, Bircher AJ, Maibach HI, Guy RH: Pharmacodynamic measurements of methyl nicotinate percutaneous absorption: the effect of aging on microcirculation. Br J Dermatol. 1990 Feb;122(2):165-71.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments>
      <attachment>
        <ref-id>F63</ref-id>
        <title>The European Agency Committee for Veterinary Medicinal Products: Methyl Nicotinate Summary Report</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/063/original/WC500015074.pdf?1526077961</url>
      </attachment>
      <attachment>
        <ref-id>F64</ref-id>
        <title>Norwegian Food Safety Authority (Mattilsynet): Methyl Nicotinate (MN) Risk Profile</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/064/original/Risk_Profile_Methyl_Nicotinate.pdf?1526078027</url>
      </attachment>
      <attachment>
        <ref-id>F65</ref-id>
        <title>Prostaglandins and nicotine-provoked increase in cutaneous blood flow</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/065/original/0d66273417ccef33671044bf478936e65155.pdf?1526078204</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated for the temporary relief of aches and pains in muscles, tendons, and joints. </indication>
  <pharmacodynamics>Following topical administration, methyl nicotinate acts as a peripheral vasodilator to enhance local blood flow at the site of application. It induced vasodilation of the peripheral blood capillaries which are located in the dermal papillae of upper dermis layers adjacent to the epidermis–dermis junction [A33027]. During tissue penetration at the dermis, methyl nicotinate is hydrolyzed to nicotinic acid [A33027]. In human volunteers, topical administration of methyl nicotinate caused vasodilation-induced generalized cutaneous erythema [A33027].</pharmacodynamics>
  <mechanism-of-action>While the mechanism of action of methyl nicotinate and other topically-administered nicotinic acid esters is not clear, it is thought that methyl nicotinate promotes the release of prostaglandin D2 that is strictly locally-acting due to its short half-life [A33027]. It was demonstrated in human subjects that the local cutaneous vascular response to methyl nicotinic was suppressed by inhibitors of prostaglandin biosynthesis, indicating that the effect of methyl nicotinate on vascular smooth muscles may be mediated by the release of local prostaglandins [F65]. Prostaglandins released from the skin and blood vessels induce cutaneous vasodilation [F65]. </mechanism-of-action>
  <toxicity>The acute subcutaneous LD50 of structurally-related nicotinamide and nicotinic acid in rats were 1.68 and 5.0 g/kg bw, respectively [F63]. In humans, oral ingestion of 3-9 g of nicotinic acid per day resulted in "niacin hepatitis", gout, and impaired glucose intolerance within a short period of time [F63]. </toxicity>
  <metabolism>Methyl nicotinate undergoes ester hydrolysis to form nicotinic acid and methanol [F64]. The hydrolysis is thought to be mediated by nonspecific α-naphthylacetate-esterase at the dermis layer of the skin [A33027]. </metabolism>
  <absorption>The presence of methyl group facilitates the penetration of methyl nicotinate through the skin with good lipophilicity, allowing rapid absorption following topical administration [F64]. _In vitro_, about 80-90% of the polar compounds methyl nicotinate rapidly penetrated the skin [F64]. It was demonstrated in excised skin of hairless mice that methyl nicotinate can effectively bypass the stratum corneum layer of the skin [F64]. In humans, nicotinic acid and nicotinamide were shown to be rapidly absorbed from the stomach and intestine via a sodium carrier-mediated mechanism at low concentrations [F64]. </absorption>
  <half-life>_In vitro_, the half-life of methyl nicotinate in the dermis was 3 to 10 minutes [A33028]. </half-life>
  <protein-binding>No pharmacokinetic data available. </protein-binding>
  <route-of-elimination>Following epicutaneous administration of small radiolabelled dose of methyl nicotinate in human volunteers, approximately 15% of the dose was recovered in the urine within 108 hours after treatment [F63]. The excretion of nicotinic acid mainly takes place in the kidneys [F63]. </route-of-elimination>
  <volume-of-distribution>According to the animal studies, nicotinic acid is mainly concentrated in the liver, kidneys, and adipose tissue [F64]. </volume-of-distribution>
  <clearance>No pharmacokinetic data available. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.</description>
    <direct-parent>Pyridinecarboxylic acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Pyridines and derivatives</class>
    <subclass>Pyridinecarboxylic acids and derivatives</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Methyl esters</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Methyl ester</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Pyridine carboxylic acid</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">3-(Carbomethoxy)pyridine</synonym>
    <synonym language="english" coder="">3-(Methoxycarbonyl)pyridine</synonym>
    <synonym language="english" coder="">3-pyridinecarboxylic acid methyl ester</synonym>
    <synonym language="english" coder="">Heat spray</synonym>
    <synonym language="english" coder="">Methyl 3-pyridinecarboxylate</synonym>
    <synonym language="english" coder="usan">Methyl nicotinate</synonym>
    <synonym language="english" coder="">Methyl-nicotinate</synonym>
    <synonym language="english" coder="">Methylnicotinate</synonym>
    <synonym language="english" coder="">Nicotinic acid, methyl ester</synonym>
  </synonyms>
  <products>
    <product>
      <name>Arth Arrest</name>
      <labeller>Key 2 Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76018-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Arth RX Topical Analgesic</name>
      <labeller>Hcd Sales</labeller>
      <ndc-id/>
      <ndc-product-code>76069-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lotion</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Arthricare for Women Multi-action</name>
      <labeller>Del Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01935046</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2005-06-20</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Arthricare for Women Nighttime</name>
      <labeller>Del Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02132095</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-01</started-marketing-on>
      <ended-marketing-on>2003-07-21</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Arthricare Pain Relieving Rub Triple Medicated Gel</name>
      <labeller>Del Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01935054</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-05</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biobalsam</name>
      <labeller>Biopharmatech Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230695</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-06-11</started-marketing-on>
      <ended-marketing-on>1999-07-07</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Decontractyl Baume</name>
      <labeller>Robert and Carriere Lab</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00167878</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1962-12-31</started-marketing-on>
      <ended-marketing-on>1998-07-22</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Midalgan</name>
      <labeller>Welcker Lyster Ltd., Division Of Technilab Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00234575</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1948-12-31</started-marketing-on>
      <ended-marketing-on>1999-09-17</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Moor Balm - Crm</name>
      <labeller>Golden Moor</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02218585</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-12</started-marketing-on>
      <ended-marketing-on>1999-06-21</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ultraplast Analgesic Spray</name>
      <labeller>Wallace, Cameron and Company Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00257036</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>2000-07-31</ended-marketing-on>
      <dosage-form>Aerosol</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Arth RX Topical Analgesic</name>
      <ingredients>Capsaicin + Methyl nicotinate</ingredients>
    </mixture>
    <mixture>
      <name>Arth Arrest</name>
      <ingredients>Capsaicin + Methyl nicotinate</ingredients>
    </mixture>
    <mixture>
      <name>Arthricare Pain Relieving Rub Triple Medicated Gel</name>
      <ingredients>Levomenthol + Methyl nicotinate + Methyl salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Arthricare for Women Multi-action</name>
      <ingredients>Capsaicin + Levomenthol + Methyl nicotinate</ingredients>
    </mixture>
    <mixture>
      <name>Midalgan</name>
      <ingredients>Capsicum + Glycol salicylate + Histamine + Methyl nicotinate</ingredients>
    </mixture>
    <mixture>
      <name>Arthricare for Women Nighttime</name>
      <ingredients>Levomenthol + Methyl nicotinate + Methyl salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Decontractyl Baume</name>
      <ingredients>Mephenesin + Methyl nicotinate</ingredients>
    </mixture>
    <mixture>
      <name>Moor Balm - Crm</name>
      <ingredients>Capsaicin + Methyl nicotinate</ingredients>
    </mixture>
    <mixture>
      <name>Biobalsam</name>
      <ingredients>Capsicum oleoresin + Methyl nicotinate</ingredients>
    </mixture>
    <mixture>
      <name>Ultraplast Analgesic Spray</name>
      <ingredients>Ethyl salicylate + Glycol salicylate + Methyl nicotinate + Methyl salicylate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Inflammatory Agents</category>
      <mesh-id>D000893</mesh-id>
    </category>
    <category>
      <category>Erythema</category>
      <mesh-id>D004890</mesh-id>
    </category>
    <category>
      <category>Inflammation</category>
      <mesh-id>D007249</mesh-id>
    </category>
    <category>
      <category>Nicotinic Acids</category>
      <mesh-id>D009539</mesh-id>
    </category>
    <category>
      <category>Pyridines</category>
      <mesh-id>D011725</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Lotion</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Aerosol</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB13882.pdf?1526078618</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.45</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>0.15</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.93e+02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>methyl pyridine-3-carboxylate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>heat spray</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>137.136</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>137.047678473</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COC(=O)C1=CN=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C7H7NO2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C7H7NO2/c1-10-7(9)6-3-2-4-8-5-6/h2-5H,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>YNBADRVTZLEFNH-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>39.19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>35.93</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>13.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>3.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble</value>
      <source>Norwegian Food Safety Authority Methyl Nicotinate (MN) Risk Profile</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>38-43</value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>209</value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.8</value>
      <source>Norwegian Food Safety Authority Methyl Nicotinate (MN) Risk Profile</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>9350</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>134761</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>7151</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347829331</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>21111785</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL379845</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB13882</drugbank-id>
        <name>Methyl nicotinate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00536</drugbank-id>
        <name>Methanol</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB13882</drugbank-id>
        <name>Methyl nicotinate</name>
      </left-element>
      <right-element>
        <drugbank-id>DB00627</drugbank-id>
        <name>Niacin</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>